The Series D round was led by Addition and will fund international expansion and product development.
"When Luca and I started TrueLayer in 2016, we imagined open banking becoming a new digital channel for solving cost and complexities around payments, digital identity, credit data and much more. We wanted to open up this newly built infrastructure to many businesses and consumers. It is such a joy to see our vision coming alive and open banking based payments quickly becoming the new normal"
The company has received funding from Innovate UK to apply its artificial intelligence platform to glioblastoma multiforme research.
"The goal of GlamAI is to break new ground in applications of AI for drug discovery and accelerate the path to personalized medicine in labs around the world. We are very proud of the progress we’ve made so far to validate our approach. Through our partnership with King’s College London, GlamAI will collaborate with experts in glioblastoma multiforme and will secure access to disease cell-lines that best represent the tumor in patients. The funding received from Innovate UK is key to progress this highly innovative project and to accelerate the path to treatment for this deadly disease."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
The Milton Keynes based dental technology firm has secured debt backing from Maven Capital Partners to launch a new browser based management system.
"The MEIF was designed to fill gaps in access to finance and provide greater options for Midlands’ businesses. Wysdom Dental is the latest investment to be made by the Fund in a technology business, enabling more new, innovative products to be developed and taken to market and supporting economic recovery following the disruption caused by the Covid-19 pandemic."
Companyon Ventures led the Series A round to accelerate product development and customer initiatives.
"With support from Companyon Ventures and Riverside Acceleration Capital, Ziflow is primed to enter its next chapter of growth and achieve its vision of helping teams review and approve content, regardless of type, device or workflow"
.png)
